May 26, 2026
Combining a potential best-in-class tissue factor-targeting ADC with anti-PD-1 therapy may enhance the anti-tumor activity of the combination due to the complementary nature of the two mechanisms Adcendo will sponsor the Phase 1b clinical trial and MSD will provide...
Apr 20, 2026
ADCE-T02, a potential best-in-class Tissue Factor targeted antibody-drug conjugate (ADC), enters cohort expansion portion of the Tiffany-01 study in advanced solid tumors Two ADCE-T02 publications highlighting important preclinical results at the 2026 AACR Annual...
Apr 14, 2026
Oversubscribed financing led by Jeito Capital, including additional new investment from Vida Ventures, BPI France, and EIFO, with participation from all existing investors Proceeds to support the advancement of three first- and best-in-class ADC programs through...
Oct 9, 2025
ADCE-D01 is a first-in-class antibody-drug conjugate targeting uPARAP, an endocytic receptor highly overexpressed in mesenchymal cancers including multiple soft tissue sarcoma subtypes Fast Track designation underscores the potential for ADCE-D01 to address the...
Aug 27, 2025
COPENHAGEN, Denmark, Aug. 27, 2025 – Adcendo, a clinical-stage biotech company pioneering the development of first and best-in-class ADCs for cancers with a high unmet medical need, today announced that management will participate in five upcoming investor...
Jun 10, 2025
ADCE-D01 is a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, an endocytic receptor highly overexpressed in mesenchymal cancers including multiple soft tissue sarcoma subtypes The ADCElerate1 trial will enroll patients in the US and Europe Copenhagen,...
